Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

Clinical Immunology

Volumn 137, Issue 1, 2010, Pages 15-20

  Johnson, Trina A ^a   Shames, Igor ^a   Keezer, Mark ^b   Lapierre, Yves ^a   Haegert, David G ^b   Bar Or, Amit ^a,b   Antel, Jack ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Fingolimod; FTY720; Lymph node; Lymphocyte; Lymphopenia; Multiple sclerosis

Indexed keywords

FINGOLIMOD;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL KINETICS; CLINICAL ARTICLE; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FUNCTION TEST; LONG TERM CARE; LUNG LESION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MEDIASTINUM LYMPH NODE; MULTIPLE SCLEROSIS; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPH NODES; LYMPHOCYTE COUNT; LYMPHOCYTES; LYMPHOPENIA; MEDIASTINUM; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT DROPOUTS; PROPYLENE GLYCOLS; RECEPTORS, CCR7; SPHINGOSINE; WITHHOLDING TREATMENT;

EID: 77956610988     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.06.005     Document Type: Article

References (14)

1. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., Haas T., Korn A.A., Karlsson G., Radue E.W. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J. Med. 2006, 355:1124-1140.
2. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 2009, 158:1173-1182.
3. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats: I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 1998, 160:5037-5044.
4. Yanagawa Y., Sugahara K., Kataoka H., Kawaguchi T., Masubuchi Y., Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats: II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J. Immunol. 1998, 160:5493-5499.
5. Chiba K., Matsuyuki H., Maeda Y., Sugahara K. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell. Mol. Immunol. 2006, 3:11-19.
6. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296:346-349.
7. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., Tiel-Wilck K., de Vera A., Jin J., Stites T., Wu S., Aradhye S., Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
8. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., Selmaj K., Agoropoulou C., Leyk M., Zhang-Auberson L., Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
9. T.A. Johnson, Y. Lapierre, A. Bar-Or, and J.P. Antel, Distinct properties of circulating CD8+ T cells in FTY720 treated multiple sclerosis patients. Archives of Neurology (2010) in press.
10. Mehling M., Brinkmann V., Antel J., Bar-Or A., Goebels N., Vedrine C., Kristofic C., Kuhle J., Lindberg R.L., Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008, 71:1261-1267.
11. Tedesco-Silva H., Mourad G., Kahan B.D., Boira J.G., Weimar W., Mulgaonkar S., Nashan B., Madsen S., Charpentier B., Pellet P., Vanrenterghem Y. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2004, 77:1826-1833.
12. Coles A., Deans J., Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin. Neurol. Neurosurg. 2004, 106:270-274.
13. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C.H. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66:460-471.
14. Kovarik J.M., Schmouder R., Barilla D., Riviere G.J., Wang Y., Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J. Clin. Pharmacol. 2004, 44:532-537.